RxDoctor Payments Data

Bridget Mikula

Family · Youngstown, OHNPI 1629534458

Payments from drug & device makers

$3,718in general payments, 2019–2025

Across 209 payments — averaging $17.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$925
  • Novo Nordisk$872
  • Corcept Therapeutics$443
  • Recordati_rare_diseases_inc.$313
  • Lilly USA, LLC$260
  • Alkermes, Inc.$167
  • plus $738 from 14 others

What the payments were for

  • Food & beverage$3,62297%
  • Education$973%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,718 in reported general payments places this provider in the 90th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$5,996
Medicare patients
47
Services billed
70

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide27$33,940
TrulicityDulaglutide25$24,136
VraylarCariprazine Hcl11$22,851
EliquisApixaban14$17,967
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$11,645
JanuviaSitagliptin Phosphate12$8,772
JardianceEmpagliflozin12$7,959
LinzessLinaclotide12$6,729
Albuterol Sulfate HfaAlbuterol Sulfate43$850
Atorvastatin Calcium138$644
Fluticasone Propionate25$610
Omeprazole48$552
Levothyroxine Sodium55$465
Gabapentin54$457
Amitriptyline Hcl15$429

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$872$33,94027 claims
AbbVieVraylar, Linzess$925$29,58023 claims
Lilly USA, LLCTrulicity$260$24,13625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,812 family providers in Ohio.

Other family in Youngstown

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →